A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor
Public ClinicalTrials.gov record NCT03235544. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2, open-label, 2-cohort study designed to evaluate the efficacy and safety of 2 parsaclisib treatment regimens in participants with relapsed or refractory mantle cell lymphoma (MCL) previously treated either with or without a Bruton's tyrosine kinase (BTK) inhibitor.
Study identification
- NCT ID
- NCT03235544
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 162 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 20, 2017 (Actual)
- Primary completion
- Apr 30, 2024 (Actual)
- Completion
- Apr 30, 2024 (Actual)
- Last update posted
- Mar 18, 2025
2017 – 2024
United States locations
- U.S. sites
- 21
- U.S. states
- 13
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama At Birmingham Comprehensive Cancer Center | Birmingham | Alabama | 35205 | — |
| St. Joseph Heritage Healthcare | Santa Rosa | California | 95403 | — |
| Rocky Mountain Cancer Center-Aurora | Aurora | Colorado | 80012 | — |
| Asclepes Research Centers | Brooksville | Florida | 34613 | — |
| Moffitt Cancer Center | Tampa | Florida | 33647 | — |
| Bond & Steele Clinic, P.A. | Winter Haven | Florida | 33880 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| Loyola University Medical Center | Maywood | Illinois | 60153 | — |
| Illinois Cancer Specialists | Niles | Illinois | 60714 | — |
| Hattiesburg Clinic Hematology | Hattiesburg | Mississippi | 39401 | — |
| Clinical Research Alliance, Inc. | New Hyde Park | New York | 11042 | — |
| Duke University Medical Center | Durham | North Carolina | 27705 | — |
| Oncology Hematology Care, Inc. | Cincinnati | Ohio | 45230 | — |
| Willamette Valley Cancer Institute | Eugene | Oregon | 97401 | — |
| Kaiser Permanente - Northwest | Portland | Oregon | 97227 | — |
| Gettysburg Cancer Center | Gettysburg | Pennsylvania | 17325 | — |
| Texas Oncology | Austin | Texas | 78705 | — |
| Texas Oncology San Antonio | San Antonio | Texas | 78240 | — |
| Renovatio Clinical | The Woodlands | Texas | 77380 | — |
| Texas Oncology - Tyler | Tyler | Texas | 75702 | — |
| Yakima Valley Memorial Hospital/North Star | Yakima | Washington | 98902 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 82 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03235544, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 18, 2025 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03235544 live on ClinicalTrials.gov.